Frank Pajonk

Dr. Frank Pajonk

Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
EVErina Vlashi
Erina Vlashi
FPFrank Pajonk
Frank Pajonk

19 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KBKruttika Bhat
Kruttika Bhat
MSMohammad Saki
Mohammad Saki
EVErina Vlashi
Erina Vlashi
FCFei Cheng
Fei Cheng
SDSara Duhachek-Muggy
Sara Duhachek-Muggy
FPFrank Pajonk
Frank Pajonk
Glioblastoma (GBM) is the deadliest adult brain cancer, and all patients ultimately succumb to the disease. Radiation therapy (RT) provides survival benefit of 6 mo over surgery alone, but these results have not improved in decades. We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion. TFP causes loss of radiation-induced Nanog mRNA expression, and activation of GSK3 with consecutive posttranslational reduction in p-Akt, Sox2, and β-catenin protein levels. TFP did not alter the intrinsic radiation sensitivity of glioma-initiating cells (GICs). Continuous treatment with TFP and a single dose of radiation reduced the number of GICs in vivo and prolonged survival in syngeneic and patient-derived orthotopic xenograft (PDOX) mouse models of GBM. Our findings suggest that the combination of a dopamine receptor antagonist with radiation enhances the efficacy of RT in GBM by preventing radiation-induced phenotype conversion of radiosensitive non-GICs into treatment-resistant, induced GICs (iGICs).

9 February 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KBKruttika Bhat
Kruttika Bhat
MSMohammad Saki
Mohammad Saki
FCFei Cheng
Fei Cheng
LHLing He
Ling He
LZLe Zhang
Le Zhang
FPFrank Pajonk
Frank Pajonk
Glioblastoma is the deadliest brain tumor in adults, and the standard of care consists of surgery followed by radiation and treatment with temozolomide. Overall survival times for patients suffering from glioblastoma are unacceptably low indicating an unmet need for novel treatment options. Using patient-derived HK-157, HK-308, HK-374, and HK-382 glioblastoma lines, the GL261 orthotopic mouse models of glioblastoma, and HK-374 patient-derived orthotopic xenografts, we tested the effect of radiation and the dopamine receptor antagonist quetiapine on glioblastoma self-renewal in vitro and survival in vivo. A possible resistance mechanism was investigated using RNA-sequencing. The blood-brain-barrier–penetrating statin atorvastatin was used to overcome this resistance mechanism. All statistical tests were 2-sided. Treatment of glioma cells with the dopamine receptor antagonist quetiapine reduced glioma cell self-renewal in vitro, and combined treatment of mice with quetiapine and radiation prolonged the survival of glioma-bearing mice. The combined treatment induced the expression of genes involved in cholesterol biosynthesis. This rendered GL261 and HK-374 orthotopic tumors vulnerable to simultaneous treatment with atorvastatin and further statistically significantly prolonged the survival of C57BL/6 (n = 10 to 16 mice per group; median survival not reached; log-rank test, P < .001) and NOD Scid gamma mice (n = 8 to 21 mice per group; hazard ratio = 3.96, 95% confidence interval = 0.29 to 12.40; log-rank test, P < .001), respectively. Our results indicate promising therapeutic efficacy with the triple combination of quetiapine, atorvastatin, and radiation treatment against glioblastoma without increasing the toxicity of radiation. With both drugs readily available for clinical use, our study could be rapidly translated into a clinical trial.

1 February 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
EVErina Vlashi
Erina Vlashi
FPFrank Pajonk
Frank Pajonk

5 June 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LHLing He
Ling He
KBKruttika Bhat
Kruttika Bhat
AIAngeliki Ioannidis
Angeliki Ioannidis
LZLe Zhang
Le Zhang
NNNhan T. Nguyen
Nhan T. Nguyen
FPFrank Pajonk
Frank Pajonk

29 August 2019 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
SDSara Duhachek-Muggy
Sara Duhachek-Muggy
KBKruttika Bhat
Kruttika Bhat
PMPaul Medina
Paul Medina
FCFei Cheng
Fei Cheng
LHLing He
Ling He
FPFrank Pajonk
Frank Pajonk
The objective of the study was to identify the mechanism of action for a radiation mitigator of the gastrointestinal (GI) acute radiation syndrome (ARS), identified in an unbiased high‐throughput screen. We used mice irradiated with a lethal dose of radiation and treated with daily injections of the radiation mitigator 1‐[(4‐nitrophenyl)sulfonyl]‐4‐phenylpiperazine to study its effects on key pathways involved in intestinal stem cell (ISC) maintenance. RNASeq, qRT‐PCR, and immunohistochemistry were performed to identify pathways engaged after drug treatment. Target validation was performed with competition assays, reporter cells, and in silico docking. 1‐[(4‐Nitrophenyl)sulfonyl]‐4‐phenylpiperazine activates Hedgehog signaling by binding to the transmembrane domain of Smoothened, thereby expanding the ISC pool, increasing the number of regenerating crypts and preventing the GI‐ARS. We conclude that Smoothened is a target for radiation mitigation in the small intestine that could be explored for use in radiation accidents as well as to mitigate normal tissue toxicity during and after radiotherapy of the abdomen. Stem Cells Translational Medicine 2019